vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and RADIANT LOGISTICS, INC (RLGT). Click either name above to swap in a different company.
RADIANT LOGISTICS, INC is the larger business by last-quarter revenue ($232.1M vs $139.2M, roughly 1.7× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 2.3%, a 33.2% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs -12.3%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $11.6M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 12.1%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Radiant Logistics, Inc. is a leading third-party logistics provider offering end-to-end supply chain solutions, domestic and international freight forwarding, warehousing, and last-mile delivery services. It primarily serves North American markets, with key client segments including retail, manufacturing, e-commerce, and industrial sectors, helping businesses optimize logistics workflows and cut operational costs.
ADMA vs RLGT — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $232.1M |
| Net Profit | $49.4M | $5.3M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 3.2% |
| Net Margin | 35.5% | 2.3% |
| Revenue YoY | 18.4% | -12.3% |
| Net Profit YoY | -55.9% | -18.0% |
| EPS (diluted) | $0.20 | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $232.1M | ||
| Q3 25 | $134.2M | $226.7M | ||
| Q2 25 | $122.0M | $220.6M | ||
| Q1 25 | $114.8M | $214.0M | ||
| Q4 24 | $117.5M | $264.5M | ||
| Q3 24 | $119.8M | $203.6M | ||
| Q2 24 | $107.2M | $206.0M | ||
| Q1 24 | $81.9M | $184.6M |
| Q4 25 | $49.4M | $5.3M | ||
| Q3 25 | $36.4M | $1.3M | ||
| Q2 25 | $34.2M | $4.9M | ||
| Q1 25 | $26.9M | $2.5M | ||
| Q4 24 | $111.9M | $6.5M | ||
| Q3 24 | $35.9M | $3.4M | ||
| Q2 24 | $32.1M | $4.8M | ||
| Q1 24 | $17.8M | $-703.0K |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | 3.2% | ||
| Q3 25 | 38.0% | 0.9% | ||
| Q2 25 | 35.1% | 2.4% | ||
| Q1 25 | 30.4% | 1.6% | ||
| Q4 24 | 32.6% | 3.3% | ||
| Q3 24 | 33.1% | 1.9% | ||
| Q2 24 | 36.6% | 2.4% | ||
| Q1 24 | 26.7% | -0.5% |
| Q4 25 | 35.5% | 2.3% | ||
| Q3 25 | 27.1% | 0.6% | ||
| Q2 25 | 28.1% | 2.2% | ||
| Q1 25 | 23.4% | 1.2% | ||
| Q4 24 | 95.2% | 2.4% | ||
| Q3 24 | 30.0% | 1.7% | ||
| Q2 24 | 29.9% | 2.3% | ||
| Q1 24 | 21.7% | -0.4% |
| Q4 25 | $0.20 | $0.11 | ||
| Q3 25 | $0.15 | $0.03 | ||
| Q2 25 | $0.14 | $0.10 | ||
| Q1 25 | $0.11 | $0.05 | ||
| Q4 24 | $0.45 | $0.13 | ||
| Q3 24 | $0.15 | $0.07 | ||
| Q2 24 | $0.13 | $0.11 | ||
| Q1 24 | $0.08 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $31.9M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $229.8M |
| Total Assets | $624.2M | $439.4M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $31.9M | ||
| Q3 25 | $61.4M | $28.1M | ||
| Q2 25 | $90.3M | $22.9M | ||
| Q1 25 | $71.6M | $19.0M | ||
| Q4 24 | $103.1M | $19.9M | ||
| Q3 24 | $86.7M | $10.4M | ||
| Q2 24 | $88.2M | $24.9M | ||
| Q1 24 | $45.3M | $31.2M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $229.8M | ||
| Q3 25 | $431.2M | $225.7M | ||
| Q2 25 | $398.3M | $226.0M | ||
| Q1 25 | $373.4M | $218.2M | ||
| Q4 24 | $349.0M | $214.4M | ||
| Q3 24 | $231.9M | $212.4M | ||
| Q2 24 | $188.3M | $209.4M | ||
| Q1 24 | $153.7M | $206.0M |
| Q4 25 | $624.2M | $439.4M | ||
| Q3 25 | $568.7M | $445.3M | ||
| Q2 25 | $558.4M | $426.8M | ||
| Q1 25 | $510.6M | $414.5M | ||
| Q4 24 | $488.7M | $386.8M | ||
| Q3 24 | $390.6M | $375.3M | ||
| Q2 24 | $376.4M | $371.2M | ||
| Q1 24 | $350.9M | $364.0M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $12.4M |
| Free Cash FlowOCF − Capex | $34.6M | $11.6M |
| FCF MarginFCF / Revenue | 24.8% | 5.0% |
| Capex IntensityCapex / Revenue | 0.8% | 0.3% |
| Cash ConversionOCF / Net Profit | 0.72× | 2.33× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $8.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $12.4M | ||
| Q3 25 | $13.3M | $2.5M | ||
| Q2 25 | $21.1M | $3.1M | ||
| Q1 25 | $-19.7M | $-5.7M | ||
| Q4 24 | $50.2M | $15.7M | ||
| Q3 24 | $25.0M | $205.0K | ||
| Q2 24 | $45.6M | $1.3M | ||
| Q1 24 | $-2.2M | $3.9M |
| Q4 25 | $34.6M | $11.6M | ||
| Q3 25 | $-1.1M | $977.0K | ||
| Q2 25 | $18.7M | $2.2M | ||
| Q1 25 | $-24.4M | $-6.4M | ||
| Q4 24 | $47.5M | $14.1M | ||
| Q3 24 | $24.0M | $-1.9M | ||
| Q2 24 | $43.6M | $-185.0K | ||
| Q1 24 | $-4.6M | $1.8M |
| Q4 25 | 24.8% | 5.0% | ||
| Q3 25 | -0.8% | 0.4% | ||
| Q2 25 | 15.3% | 1.0% | ||
| Q1 25 | -21.2% | -3.0% | ||
| Q4 24 | 40.4% | 5.3% | ||
| Q3 24 | 20.0% | -0.9% | ||
| Q2 24 | 40.7% | -0.1% | ||
| Q1 24 | -5.6% | 1.0% |
| Q4 25 | 0.8% | 0.3% | ||
| Q3 25 | 10.7% | 0.7% | ||
| Q2 25 | 2.0% | 0.4% | ||
| Q1 25 | 4.1% | 0.3% | ||
| Q4 24 | 2.3% | 0.6% | ||
| Q3 24 | 0.9% | 1.0% | ||
| Q2 24 | 1.9% | 0.7% | ||
| Q1 24 | 2.9% | 1.2% |
| Q4 25 | 0.72× | 2.33× | ||
| Q3 25 | 0.36× | 1.90× | ||
| Q2 25 | 0.62× | 0.63× | ||
| Q1 25 | -0.73× | -2.26× | ||
| Q4 24 | 0.45× | 2.43× | ||
| Q3 24 | 0.70× | 0.06× | ||
| Q2 24 | 1.42× | 0.26× | ||
| Q1 24 | -0.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
RLGT
| Transferred Over Time | $201.2M | 87% |
| Other | $25.0M | 11% |
| Value Added Services | $4.2M | 2% |
| Transferred At Point In Time | $1.8M | 1% |
